SciSparc Ltd. is a clinical-stage pharmaceutical company that develops drugs using cannabinoid molecules for various medical conditions such as Tourette syndrome, sleep apnea, Alzheimer's disease, and pain relief. The company has partnered with Procaps and Sheba Fund for Health Services and Research to manufacture and examine the potential of SCI-110 and SCI-210 respectively. Formerly known as Therapix Biosciences Ltd., the Israeli-based company was incorporated in 2004 and is now headquartered in Tel Aviv.